Press Release

ZEISS leads funding round for Surgify Medical to drive safety in surgical procedures

Series A funding will enable acceleration of development and commercialization of tissue-selective power tools in the EU and the US.

28 May 2025

Oberkochen, Germany | 28 May 2025 | ZEISS Group

The company Surgify Medical has announced that it has raised seven million euros in a Series A funding round. ZEISS Ventures led this round with participation from – amongst others – Lednil, Cascara Ventures and the European Innovation Council Fund (EIC Fund). Surgify Halo^™ burrs have regulatory approval under MDR and FDA 510(k), so the investment will enable the company to accelerate the commercialization of its pioneering technology across the European Union and the United States.

Surgify Medical’s patented Surgify Halo^™ technology features a mechanism providing unique protective capabilities against incidental injuries to easily damageable soft tissue during bone resections.

Founded in 2017 as a spin-out from Aalto University in Finland, Surgify Medical is specialized in the development and commercialization of surgical power tools. Its patented Surgify Halo^™ technology provides unique protective capabilities against incidental injuries to easily damageable soft tissues such as central nervous system structures, blood vessels, and nerves during bone resections.

“We are thrilled to welcome ZEISS Ventures and the EIC Fund as partners in our journey,” says Visa Sippola, Co-founder and CEO of Surgify Medical. “With this funding and FDA and MDR clearance, we are well positioned to bring our unique technology to more surgeons and patients internationally.”

“We are excited to partner with Surgify in their mission to establish a new benchmark for surgical safety. Surgify’s Halo^™ burrs offer exceptional control at cutting rates comparable to traditional burrs, while simultaneously safeguarding delicate soft tissues. This makes the switch to Halo™ burrs an obvious choice for surgeons,” explains Dr. Boris Hofmann, Head of ZEISS Ventures. “We are eager to support the team as they expand their solution on a global scale.”

Soft tissue damage is considered a highly relevant surgical complication in many types of head, neck and spine procedures involving bone resection and is estimated to cause more than four billion euros in complication-related costs annually in a global context.

Press Contact Julian Bosch

Corporate Brand, Communications and Public Affairs
ZEISS Group

About ZEISS

ZEISS is an internationally leading technology company in the optics and optoelectronics industry. The ZEISS Group generated annual revenue totaling around 11 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology (updated: 30 September 2024).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Industry 4.0 as well as a strong brand, ZEISS is shaping technological progress and, through its solutions, is extending the horizon of the world of optics and associated areas. ZEISS' significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14% of its revenue in research and development work – ZEISS has a long tradition of high expenditure in these areas. This also represents the company's investment in the future.

With more than 46,555 employees, ZEISS operates in around 50 countries with more than 60 sales and service sites, 40 research and development sites and 35 production sites worldwide (as of 31 March 2025). The headquarters of the company, which was founded in Jena in 1846, is located in Oberkochen, Germany. The Carl Zeiss Foundation, one of Germany’s largest foundations committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

About Surgify

Surgify Medical, based in Espoo, Finland, is dedicated to revolutionizing bone surgery by making it safer, faster, and more precise. The company’s flagship product, Surgify Halo™, is designed to differentiate between hard and soft tissues, providing enhanced protection against incidental soft tissue damage and streamlining procedures.”

The benefits of Surgify Halo™ extend beyond its core market of head, neck, and spine surgeries. Surgify’s technology also has the potential to revolutionize the growing field of robotic surgery by enabling reliable automated bone resection.

In 2024, the Surgify Halo™ was awarded the prestigious Red Dot Award: Innovative Product 2024, earning international recognition for its exceptional design, advanced materials, and pioneering approach to surgical innovation.

To date, Surgify Medical has raised 14 million euros in total funding and has offices in Finland, Sweden, Denmark, and the United States.

For more information, visit www.surgifymedical.com